BioVie: Funding, Investors & Team (Oct 2026)
Focusing on Finding Solutions for Healthier Brain, Memory, and Movement. Our neurology strategy is centered at what we understand to be the nexus of biochemistry, cellular energetics, and neuroprotection, enabling us to explore the potential of our pipeline molecules to decrease inflammation, enhance glucose utilization, protect neurons, and facilitate energy transfer within the central nervous system, ultimately leading to improvements in memory and movement, and a healthier brain. Our lead Neuroscience molecule (NE3107) is currently being investigated in human clinical studies to assess its hypothesized impact on both Alzheimer’s and Parkinson’s. Exploring the possibilities of improved outcomes, fewer medical burdens, and more time at home. In our cirrhosis studies, we are working to learn if our exploratory technology can help individuals who have been diagnosed with cirrhosis-related ascites (fluid that builds up inside the abdomen) to be more comfortable, to require fewer or less frequent medical procedures to drain ascites fluid, and to see if the treatment can help people with ascites to live outside of the hospital for longer periods of time. BioVie is currently investigating BIV-201, a novel formulation of terlipressin, in human clinical trials. In BioVie’s studies of BIV-201, the exploratory medication is provided as a continuous infusion formulation delivered by a small, portable pump that the user can wear while engaging in typical tasks and activities at home. For more information about BioVie and our current studies, please visit our website https://bioviepharma.com/
BioVie has raised $18.7M across 2 funding rounds on record, the most recent an undisclosed round of $12.0M announced in Aug 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioVie Company Profile and Key Stats
Latest funding round on record: Aug 2025.
BioVie Funding Rounds
BioVie raised $6.7M in an undisclosed round announced in Oct 2024.
10 months later, an undisclosed round of $12.0M was announced in Aug 2025.
BioVie Founders and Leadership Team
No contact details are on record for this team yet.
BioVie Funding Compared to Other Biotechnology Startups
BioVie's latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioVie in Biotechnology and Beverly
Companies Similar to BioVie
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
BioVie Funding FAQs
What does BioVie do?
Focusing on Finding Solutions for Healthier Brain, Memory, and Movement. Our neurology strategy is centered at what we understand to be the nexus of biochemistry, cellular energetics, and neuroprotection, enabling us to explore the potential of our pipeline molecules to decrease inflammation, enhance glucose utilization, protect neurons, and facilitate energy transfer within the central nervous system, ultimately leading to improvements in memory and movement, and a healthier brain. Our lead Neuroscience molecule (NE3107) is currently being investigated in human clinical studies to assess its hypothesized impact on both Alzheimer’s and Parkinson’s. Exploring the possibilities of improved outcomes, fewer medical burdens, and more time at home. In our cirrhosis studies, we are working to learn if our exploratory technology can help individuals who have been diagnosed with cirrhosis-related ascites (fluid that builds up inside the abdomen) to be more comfortable, to require fewer or less frequent medical procedures to drain ascites fluid, and to see if the treatment can help people with ascites to live outside of the hospital for longer periods of time. BioVie is currently investigating BIV-201, a novel formulation of terlipressin, in human clinical trials. In BioVie’s studies of BIV-201, the exploratory medication is provided as a continuous infusion formulation delivered by a small, portable pump that the user can wear while engaging in typical tasks and activities at home. For more information about BioVie and our current studies, please visit our website https://bioviepharma.com/
How much funding has BioVie raised?
BioVie has raised $18.7M across 2 rounds on record. The most recent is an undisclosed round of $12.0M announced in Aug 2025.
When did BioVie last raise funding?
BioVie's most recent funding round on record is an undisclosed round of $12.0M, announced in Aug 2025.
Who founded BioVie?
FundedIQ lists O E Campbell (Founder) at BioVie.
Where is BioVie headquartered?
BioVie is based in Beverly, Massachusetts, United States.
How many employees does BioVie have?
BioVie is in the 11-50 employee band.
How does BioVie's funding compare to other Biotechnology startups?
BioVie's latest round of $12.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BioVie Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioVie is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.